Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
WuXi XDC Cayman: major shareholder places shares to raise capital – stock falls
A major shareholder of WuXi XDC Cayman, STA Pharmaceutical Hongkong, placed 53.5 million shares at HK$73.23 each, apparently aiming to raise up to US$500 million. The news came with a substantial discount to the previous close and triggered a price drop of about 2.6% to HK$75.25. There was also profit-taking after WuXi’s strong half-year results. » More on de.investing.com
WuXi XDC posts first-half profit above RMB 1 billion — shares rise about 15%
WuXi XDC reported H1 2026 revenue of RMB 3.7 billion (+37% year‑on‑year) and an adjusted net profit of over RMB 1 billion. Gross margin improved to 37% and order backlog rose to over USD 2 billion, including around USD 120 million of commercial orders. The stock climbed 14.8% to USD 80.15. Management reaffirmed the full-year guidance (consolidated currency‑adjusted revenue growth ~30%, standalone ≥35%) and highlighted effects from the ramp‑up of the new Singapore site and integration costs related to BioDLink. » More on de.investing.com
WuXi XDC rises almost 12% after strong H1 results
WuXi XDC reported H1 2026 revenue of RMB 3.701 billion (+37% yoy) and an adjusted net profit attributable to shareholders of about RMB 1.027 billion (+37.4%). Gross margin improved to 37.0% and management cited the integration of BioDlink, the expansion of the global production network (including commercial production in Singapore) and the further development of its own technology platforms as drivers of structural growth. The stock then climbed roughly 12% to HK$78. » More on de.investing.com
Akari starts GMP production of AKTX-101 in partnership with WuXi XDC
Akari Therapeutics has begun GMP-compliant manufacture of its lead ADC program AKTX-101 in an exclusive partnership with WuXi XDC to supply material for regulatory IND-enabling studies. AKTX-101 uses Akari’s PH1 payload, which modulates RNA splicing, and showed high efficacy versus traditional ADCs in preclinical studies. The company plans first-in-human phase 1 studies in about 12 months (end of 2026/early 2027, pending regulatory clearance), recently raised roughly $5 million in fresh capital, received a NASDAQ notice of non-compliance with the minimum bid price requirement, and appointed an interim CFO. » More on de.investing.com
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 470.77m | - |
| Gross profit | 174.42m | - |
| Net profit | 104.04m | - |
| EBITDA | 152.19m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €9.71bn |
Number of shares | 1.27bn |
52-week high/low | €9.95 - €5.06 |
| Dividends | No |
Beta | -0.78 |
P/E ratio | 45.95 |
PEG ratio | 2.09 |
P/B ratio | 6.24 |
P/S ratio | 10.29 |
Company profile
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
| Name | WuXi XDC Cayman Inc |
| CEO | Jincai Li |
| Headquarters | Wuxi,
js China |
| Website | |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| IPO | 18/06/2012 |
| Employees | 2,662 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Düsseldorf | L74.DU |
Frankfurt | L74.F |
München | L74.MU |